AstraZeneca halts several mid- and late-stage trials after efficacy setbacks

AstraZeneca announced it has stopped a number of mid- and late-stage clinical trials in its pipeline over recent months.

The decision follows disappointing efficacy results in those studies, limiting the company's ability to extend the life cycle of the affected products.

Analysts note the cuts could reshape AstraZeneca's pipeline strategy and may temper expectations for future revenue growth, though the company did not name the specific programs.